The supply crunch is expected to last until at least 2028.

Explainer: RSV may not quite have the name recognition, but it's actually causing more winter illness.

The FDA’s Office of Prescription Drug Promotion recently reprimanded Sanofi and Viatris for making misleading claims about their products in emails and a television advertisement. FDA issued an ...

Most Americans are unaware or unsure of which vaccines the Centers for Disease Control and Prevention (CDC) recommends during ...

Viral infections that attack the lungs are among the leading reasons infants are hospitalized. A new treatment may offer ...

The FDA has called out Sanofi’s promotion of respiratory syncytial virus (RSV) antibody Beyfortus in a new untitled letter, ...

A U.K. marketing watchdog has reprimanded Sanofi for using “a highly misleading interpretation of data” to make disparaging ...

In the latest pair of Untitled Letters, the FDA took issue with a Viatris TV ad and Sanofi’s promotional emails.

Health experts are warning winter viruses are yet to peak, with children back in classrooms expected to drive another wave of ...

Based on these findings, Seek Labs is initially advancing SeekIt toward applications in respiratory diagnostics and biosecurity, with a focus on settings where rapid, lab-independent molecular testing ...

The long-acting monoclonal antibody clesrovimab (Enflonsia) was well tolerated in infants at increased risk for severe ...